Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial

pemvidutide (ALT-801) - Altimmune

JOHN J. SUSCHAK; BERTRAND GEORGES; M S. ROBERTS; M. SCOTT HARRIS; SARAH K. BROWNE

May 21, 2024